Market Overview

The global insulin patch pumps market in terms of revenue was estimated to be worth $ 5.21 Billion in 2023 and is poised to reach $ 21.06 Billion by 2032, growing at a CAGR of 16.8%%from 2024 to 2032.

The main drivers for the rapid growth are new technologies, an increased population with diabetes, and enhanced awareness of advanced patch pumps. According to the International Diabetes Federation, in 2022, about 537 million adults had diabetes, and this figure is estimated to reach 643 million by 2030. Since the insulin infusion set is not required in insulin patch pumps, they are more in demand among people diagnosed with type 1 diabetes. As it is simple in them, working classes and older age groups like them more.

Since insulin patch pumps are less noticeable, easier to operate, and smaller in size as compared to traditional insulin pumps, they work like efficient machines. Compared to traditional pumps, these are more affordably priced, which in turn increases the demand. To affix the pump to the skin, an adhesive layer is used. Because of their high technology, these pumps have less monitoring. Generally, these pumps are easily incorporated into continuous glucose monitoring or blood glucose monitoring systems.

This technology is most probably going to replace, in large measure, the traditional vial-syringe combinations. Market competition will also rise due to increasing releases of new products and agreements among developers of technology and major players in the industry. Tandem Diabetes Care, for example, is manufacturing a t: sport insulin pump that will be half the size of its t: slim X2. The devices are likely to have a robust rise in demand within the period of forecast due to the wide range of customized patch pumps available.

One of the primary reasons for the growing use of these devices among the young population is their subtle nature. The rising global cases of diabetes are also expected to create profitable opportunities for innovative diabetic treatment products, such as patch pumps. According to the International Diabetes Federation, there would be 783,700 diabetics across the globe by 2045, which would comprise a large percentage of the geriatric population as well. The same source reports that about 6 million Americans use insulin to manage their diabetes.

The COVID-19 pandemic does have the risk of greater cases of infections, mortality, and worse complications- ischemic heart disease, and even renal damage-from people having diabetes. This is especially so because the main constraint comes down to finances as 20.0% reported that in some measure it is difficult for them to timely refilled their pumps, while a fifth stated that is equally challenging finding blood glucose monitors. It has been caused by production site closures, transportation delays or shutdowns, as well as imposed trade restrictions or export prohibition on life-saving medications such as insulin.

Key Findings

• Ceiling rate for basic version of Insulin Pump are fixed at 2 Lakhs.
• Ceiling rate for a sensor-augmented Insulin Pump are fixed at Rs. 3.0 Lakhs.
• In addition, the monthly cost for the consumables is fixed at Rs 5,000/-

Market Drivers

• Increased Focus on Automation

Rapid advances in technologies and novel focuses on more patient-centred care for diabetic patients drive the trend in the automation of insulin-delivery systems. Such automated devices will automatically alter the taking of an insulin dose based on readouts provided by continuous glucose monitoring. Beyond the significant user-friendliness potential, this feature promises greatly enhanced glucose control at significantly reduced hazards of hypoglycaemia and hyperglycaemia.

For example, the closed-loop system hybrids can allow direct communication with an insulin pump to deliver a personal dose of insulin at all times​.Automated devices save one from the hassles of doing tedious calculations and constant checking, therefore enabling a patient to lead a less confined daily life with proper control of diabetes​

Awareness over these benefits will increase further demand for advanced patch pumps, similar in functionalities which further expands the market presence​It is a step that transforms to more effective personalized diabetes management by including smart technologies as treatment options.

Key Findings

• As per Utah: In the US, approximately 350,000 to 515,000 patients with diabetes use CSII29; >35,000 patients using CSII are estimated to have T2D.30 CSII (also called insulin pump therapy) imitates the natural secretion of insulin by constantly infusing insulin at a basal rate and allowing for bolus doses when needed (either manually or automatically depending on the device).

Market Opportunities

• Patient Education and Awareness

Increasing knowledge and teaching about the management of diabetes is very important in increasing insulin patch pump adoption. Other patients are least likely to be knowledgeable regarding patch pumps' benefits, such as the use being convenient, simple, and even integrating real-time glucose monitoring systems. Companies, that focus more on the patient educational activities, can educate and thus attract more customers to use this particular drug. The company can increase the awareness level by funding educational activities such as workshop, webinars, and also educational material to inform the patient about his/her options to manage diabetes. In such a scenario, the benefits of the patch pump will have the companies create a positive awareness and image of the brand and thus help them to continue on top of the marketplace.

Besides, educating the healthcare providers about the latest technologies influences their recommendations to the patients. The more people get educated about the availability and benefits of advanced insulin delivery systems, the higher the growth will be in the market for insulin patch pumps. Developing an informed patient base can increase patient outcomes, allowing companies to gain the competitive edge in the always-evolving landscape of diabetes care.

Key Findings

• The U.S. FDA authorised Roche Diabetes' Accu-Chek Solo micropump in September 2023.
• The Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software were approved by the U.S. FDA in May 2023 for use by people with type 1 diabetes who are six years of age or older.

Market Restraining Factors

• Cost Barriers to Adoption of Insulin Patch Pumps

Among the most basic problems in using insulin patch pumps is their comparative higher cost than conventional means of using insulin, including syringes and insulin pens. Of course, the expenses are a burden to the patients, especially those not insured or underinsured. Many people with diabetes must carefully consider the cost of their medical care, and the increased price of patch pumps may act as a deterrent to changing a less expensive system, even though a more expensive system might otherwise offer greater ease and glycaemic control benefits​On-going supplies, such as adhesive patches and insulin cartridges, may also increase the overall expense. This may be hard for the patients to justify that the cost of the device may significantly make their quality of life but is expensive​So, the manufacturers who need to increase market penetration must focus on such issues related to cost. For instance, the company might include financial assistance programs or collaborate with insurance companies for better coverage.

Segmentation Analysis

The market scope is segmented because of by Product Type, by End-User, by Application, by Technology, by Distribution Channel, by Patient Type, by Pricing Model, by Region.

• By Product Type

Based on the Product Type of the market is segmented into Wearable Insulin Patch Pumps, Wireless Insulin Patch Pumps, Smart Insulin Patch Pumps.

Wearable insulin patch pumps hold the majority of the market share in delivering insulin since they have the advantages of convenience and effectiveness over the management of diabetes in a patient. These medical devices stick directly to the surface of the skin and continue to deliver insulin through a little cannula or needle attached to it, thus bypassing the need for one or more injections per day. For instance, Omni pod remains one of the most wearable insulin patch pumps with tubing, tubeless, waterproof design to ensure easy convenience for users. Apart from the wearable, there now has wireless insulin patch pumps through the usage of wireless technologies, ensuring patients are convenient and interact with the machines. These devices enable individuals to change the amount of insulin to be administered and to monitor the levels of blood glucose using cellular applications. Furthermore, it equips advanced features like CGM and smartphone connectivity by new smart insulin patches that are monitoring data in real-time for the automatic adjustment of insulin supply in patients. These devices represent innovation in diabetes management that shows a better fit to differently diversified patient needs and towards greater compliance with prescribed treatment plans.

• By End-User

Based on the End-User of the market is segmented into Hospitals, Home Care, Diabetes Clinics.

Currently, most of the insulin delivery systems used in the worldwide market is dominated by the wearing insulin patch pump, primarily due to convenience and efficiency in managing diabetes. It can directly stick onto the skin where insulin can be infused using a small cannula or needle for constant infusion of insulin without requiring injections throughout the day. An example is the Omni pod patch pump, which is highly user-friendly for active persons and provides insulin delivery from a tubeless, waterproof design. In addition, there are wireless insulin patch pumps that have been developed incorporating wireless technology to allow the monitoring and control of diabetes remotely, thus making this even more convenient for the patient and increasing patient empowerment. The insulin pumps enable users to adjust the delivery of insulin and track their glucose levels using mobile applications. Moreover, smart insulin patch pumps come with features such as continuous glucose monitoring and smartphone connectivity, which enable users to monitor data in real-time and for the insulin pump to adjust automatically. Together, these innovations represent a step forward in diabetes management that can be tailored to address the needs of patients as effectively as possible and encourages them to adhere to the treatment plan.

• Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America is the most significant market for insulin patch pumps, primarily driven by a high prevalence of diabetes and robust health care infrastructure. The region boasts of superior medical technology as well as relatively high disposable incomes, which makes it more effortless to introduce newer and more technologically advanced infusion devices for insulin. It is the US that forms the most dominant market, and this is because there exists an enormous number of patients under insulin therapy. Constant innovative features in devices by majors like Medtronic and Insulet are also ensuring growth in the market, but supporting reimbursement policies are enhancing growth within the market even further.

Europe is one of the major shareholders in the global insulin patch pumps market due to growing awareness related to the management of diabetes and investment in health care. As of now, the leading countries that adopt such insulin delivery systems are Germany, France, and UK. Moreover, it is noticed that there is a growing demand for smart insulin patch pumps that suit perfectly with CGM systems in the Europe region. Such agencies as the European Medicines Agency support new technologies to be quickly integrated with regulatory support.

The Asia-Pacific region is the fastest-growing market for insulin patch pumps because of the rising cases of diabetes and improvement in healthcare access. The incidence of diabetes is increasing due to lifestyle changes and urbanization in countries such as China and India. The middle class in these countries demands diabetes management solutions. The low-cost insulin delivery systems developed by emerging local manufacturers further stimulate growth in this market.

Latin America is still undergoing an increasing market of insulin patch pumps. Market growth mainly arises due to Brazil and Mexico's increasing awareness toward the diabetes conditions along with the increasing demand for effective management systems. However, few barriers in this direction are that lack of accessibility towards advanced healthcare technology, expensive products, but improved health structures and easy medication access hold a vital role in forwarding the market of this area.

The market for insulin patch pumps in the Middle East and Africa is in development. Changes in lifestyles and urbanization lead to an increase in the incidence of diabetes cases. Markets are still at a budding stage but encounter challenges, such as not enough infrastructures for health care, and the medical equipment of advanced technology tends to be expensive. They will still invest in governmental and private health care advancements and education programs on diabetes, which may eventually help them reap the benefits.

In the overall context, the global insulin patch pumps market is expected to grow significantly, with North America being at the forefront, followed by Europe and the Asia-Pacific region, which is expanding rapidly. With growing awareness and technology, all the regions are expected to make progress in diabetes management solutions.

List of Companies Profiled

• Medtronic plc
• Hoffmann-La Roche Ltd.
• Insulet Corporation
• CeQur
• Terumo
• Tandem Diabetes Care
• Medtrum
• Ypsomed AG
• Microtec Medical Ltd
• ViCentra B.V.
• SOOIL Developments Co., Ltd
• EOFLOW CO., LTD.

Key Industry Developments

• In January 2024, PharmaSens, a medical device firm based in Switzerland, applied to the FDA for approval of their novel insulin pump. In November 2023, the business obtained ISO 13485 accreditation.
• In February 2023, Automated Glucose Control (AGC) LLC, a business dedicated to creating and promoting automated insulin delivery technology, has acquired a number of assets from Insulet Corporation, a world leader in tubeless insulin pump technology.
• In January 2023, the acquisition of AMF Medical SA, a privately held Swiss company that develops the Sigi patch pump, has been completed, according to Tandem Diabetes Care, Inc. By employing pre-filled insulin cartridges, the Sigi patch pump, a rechargeable gadget, lessens the strain of treating diabetes.
• In March 2022, in order to sell and distribute EOFlow's wearable insulin pump (EOPatch) in the Middle East, GulfDrug LLC, a distributor of pharmaceuticals and medical devices, signed a contract with EOFLOW CO., LTD.
• In February 2022, The FDA approved Tandem Diabetes Care, Inc.'s mobile bolus function, which enables t:slim X2 patients to manage an insulin bolus via their smartphone and the t:connect mobile app.
• In May 2021, Under the mySugr app, F. Hoffmann-La Roche Ltd. introduced mySugr Pump Control. Patients can import and view data status using a smartphone to directly operate their insulin pumps using mySugr Pump operate.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Insulin Patch Pumps Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Insulin Patch Pumps market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Insulin Patch Pumps. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Insulin Patch Pumps companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Insulin Patch Pumps Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Insulin Patch Pumps Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Insulin Patch Pumps Market valued?
• Which region has the largest share in 2024 for the global Insulin Patch Pumps Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of the Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Insulin Patch Pumps Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: